9 out of 10 patients who got the immunotherapy for Hodgkin Lymphoma were in remission after two years – Wilmot Cancer Institute

Wilmot Cancer Institute recently posted on LinkedIn:

“Exciting news!

A new study just published in the New England Journal of Medicine (NEJM Group) and led by Dr. Jonathan Friedberg reports that an immunotherapy treatment called nivolumab combined with chemo boosted the survival rate for Hodgkin lymphoma to 92%, compared to the current standard of care.

That means that 9 out of 10 patients who got the immunotherapy in this clinical trial were in remission after two years.

The study is important for several reasons:

• It enrolled nearly 1,000 patients from institutions around the country, including Wilmot, some as young as 12.
• Investigators were trying to raise the cure rate while also reducing side effects associated with older treatments, which can include second cancers later in life and other health problems.
• Hodgkin lymphoma is a disease that often impacts young people and the goal was to set them on a path that will allow them to live for decades with fewer risks of harm.

Ongoing basic and clinical research is what leads to cutting-edge cancer care!”

Read further.

More posts featuring Wilmot Cancer Institute.